Chemical formula: C₃₀H₃₄N₂O₃  Molecular mass: 470.613 g/mol  PubChem compound: 154257

Therapeutic indications

Bazedoxifene is indicated for:

Postmenopausal osteoporosis

Population group: women, only adults (18 years old or older)

Bazedoxifene is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.

When determining the choice of bazedoxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

For this indication, competent medicine agencies globally authorize below treatments (click for details):


Bazedoxifene is contraindicated in the following cases:





Venous thromboembolic events

at least one of
Pulmonary embolism
Venous embolism
Thromboembolism of vein
History of venous thromboembolic disease

Unexplained uterine bleeding

Abnormal uterine bleeding unrelated to menstrual cycle

Signs or symptoms of endometrial cancer

Primary malignant neoplasm of endometrium

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.